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vaccines co-delivered in the nasal cavity of nonhuman primates
Jeremy V. Camp a, Robert L. Wilson a, Morgan Singletary b, James L. Blanchard b, Anna Aldovini c,
Robert W. Kaminski d, Edwin V. Oaks d, Pamela A. Kozlowski a,⇑
a

Department of Microbiology, Immunology, and Parasitology, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA
Tulane National Primate Research Center, Division of Veterinary Medicine, Covington, LA 70433, USA
Departments of Medicine and Pediatrics, Children’s Hospital and Harvard, Boston, MA 02115, USA
d
Department of Subunit Enteric Vaccines and Immunology, Division of Bacterial and Rickettsial Diseases, The Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA
b
c

a r t i c l e

i n f o

Article history:
Received 16 February 2021
Received in revised form 4 May 2021
Accepted 11 June 2021
Available online 24 June 2021
Keywords:
HIV/AIDS
IgA
Mucosal adjuvant
Reproductive
Respiratory tract

a b s t r a c t
Development of intranasal vaccines for HIV-1 and other mucosal pathogens has been hampered by the
lack of adjuvants that can be given safely to humans. We have found that an intranasal Shigella vaccine
(Invaplex) which is well tolerated in humans can also function as an adjuvant for intranasal protein and
DNA vaccines in mice. To determine whether Invaplex could potentially adjuvant similar vaccines in
humans, we simultaneously administered a simian immunodeficiency virus (SIV) envelope (Env) protein
and DNA encoding simian-human immunodeficiency virus (SHIV) with or without Invaplex in the nasal
cavity of female rhesus macaques. Animals were intranasally boosted with adenoviral vectors expressing
SIV env or gag,pol to evaluate memory responses. Anti-SIV antibodies in sera and nasal, genital tract and
rectal secretions were quantitated by ELISA. Intracellular cytokine staining was used to measure Th1-type
T cells in blood. Macaques given DNA/protein immunizations with 0.5 mg Invaplex developed greater
serum IgG, nasal IgA and cervicovaginal IgA responses to SIV Env and SHIV Gag,Pol proteins when compared to non-adjuvanted controls. Rectal IgA responses to Env were only briefly elevated and not
observed to Gag,Pol. Invaplex increased frequencies of IFNc-producing CD4 and CD8 T cells to the Env
protein, but not T cell responses induced by the DNA. Ad-SIV boosting increased Env-specific polyfunctional T cells and Env- and Gag,Pol-specific antibodies in serum and all secretions. The data suggest that
Invaplex could be highly effective as an adjuvant for intranasal protein vaccines in humans, especially
those intended to prevent infections in the genital or respiratory tract.
Ó 2021 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction
Vaccines for respiratory pathogens are typically administered
by the intramuscular (IM) route, which does not induce immune
responses specifically in the respiratory tract [1,2] but does generate serum antibodies that eliminate pathogens inside the host.
Intranasal (IN) vaccines may be optimal for preventing infections
by respiratory pathogens as they generate local secretory IgA
(S-IgA) respiratory tract antibodies that could prevent pathogen
Abbreviations: Ad, adenovirus; CVS, cervicovaginal secretions; Env, envelope;
ICS, intracellular cytokine staining; IM, intramuscular; IN, intranasal; NHP, nonhuman primates; NS, nasal secretions; RS, rectal secretions; S-IgA, secretory IgA; Th, T
helper.
⇑ Corresponding author at: LSUHSC, CSRB Box 6-16, 533 Bolivar Street, New
Orleans, LA 70112, USA.
E-mail address: pkozlo@lsuhsc.edu (P.A. Kozlowski).

entry into the body altogether. Indeed, in animal studies,
influenza-specific IgA in nasal secretions has been shown more
effective than serum IgG neutralizing antibodies for preventing
airborne transmission in the upper respiratory tract [3–6]. IN
immunization has also been found more effective than IM immunization for preventing a variety of respiratory infections in animals [7–11]. Thus, new nasal vaccines for respiratory syncytial
virus and other respiratory pathogens are being tested in humans
[12–15].
The nasal vaccination route is the only mucosal route shown to
be capable of inducing humoral and cellular immune responses in
multiple mucosal tissues and the systemic compartment of
humans and nonhuman primates (NHP) [16–19]. Tissues populated by effector lymphocytes after nasal immunization include
the female genital tract and large intestine [20,21]. Therefore,
delivery of vaccines by the nasal route could be an effective
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strategy for preventing infections by sexually-transmitted pathogens, such as human immunodeficiency virus type 1 (HIV). Indeed,
IN administration of a ‘‘T cell-inducing” DNA/recombinant modified vaccinia ankara (MVA) virus vaccine for SIV resulted in greater
control of SIVmac251 vaginal and rectal infection in rhesus
macaques [22,23] when compared to IM immunization with the
same products. An ‘‘antibody-inducing” HIV vaccine given by both
IN and IM routes also protected macaques against vaginal
simian-human immunodeficiency virus (SHIV) challenge whereas
IM vaccination alone did not [24].
The correlates of protection against HIV have not been
precisely defined but there is evidence that optimal vaccinemediated protection will require induction of serum IgG
antibodies that neutralize or mediate antibody-dependent cellular cytotoxicity, and Th1-type antiviral CD8 T cells, especially in
exposed mucosal tissues [25,26]. Vaccine-induced mucosal
antiviral IgA responses at the site of viral challenge have also
been associated with protection or control of infection in several
NHP HIV vaccine studies [24,27–29]. However, effective induction
of mucosal IgA responses will require mucosal delivery of
vaccine, and a strong adjuvant to prevent tolerance. Cholera toxin
and the closely related E. coli heat-labile toxin have proved most
effective as mucosal adjuvants in animals, and many nontoxic
derivatives of these enterotoxins have been created for use as
mucosal adjuvants in humans [30,31]. Unfortunately, most cannot
be administered in the nasal cavity due to their propensity to
bind to nerve endings and cause Bell’s Palsy [32]. To our knowledge, the only products that have clearly been demonstrated both
safe and effective as nasal adjuvants in humans are chitosan [33]
and Protollin, consisting of Shigella flexneri lipopolysaccharide
(LPS) and Neisseria meningitides outer membrane proteins
[34,35]. Thus, there is a need to identify more nasal adjuvants
for use in humans.
Invaplex 50 is native structure isolated from wild-type Shigella and consists of Shigella flexneri 2a LPS complexed with
two invasion plasmid antigen (Ipa) proteins, IpaB and IpaC
[36], which are key effector proteins of the type-three secretion
system. Invaplex 50, which is retrospectively termed Native
Invaplex or InvaplexNAT, induces endocytosis and facilitates
cytosolic delivery of co-administered antigens. Invaplex was
originally developed as a nasal subunit Shigella vaccine [37],
and in a recent Phase I study, dosages as high as 0.69 mg were
reported safe in the human nasal cavity [38]. In addition to
preventing Shigella infection in mice [36], Invaplex has acted
as an IN adjuvant for co-administered protein immunogens or
DNA vaccine in this species [39,40]. However, results in
IN-immunized mice do not always extrapolate to humans, possibly because the nasal cavity of rodents contains more immuneinductive lymphoid tissue than primates [41].
To better ascertain whether Invaplex could potentially adjuvant
nasal vaccines in humans, we performed a pilot study testing its
ability to enhance systemic and mucosal antibody responses in
rhesus macaques given simultaneous IN vaccinations with an SIV
Env protein and a model DNA vaccine that encodes noninfectious
SHIV89.6P particles [22]. The ability to generate B cell memory
was evaluated by measuring anamnestic antibody responses after
a IN boost with adenoviral type 5 (Ad5) vectors expressing SIV
env and SIV gag-pol. Because Invaplex can act, in a non-toxic manner, as a transporter of DNA or complexed immunogens into the
cytosol of antigen-presenting cells [40], potentially leading to the
activation of antigen-specific CD8 T cells, we also evaluated frequencies of T helper type 1 (Th1)-type SIV-specific CD8 T cells.
The results indicate that Invaplex can function as an adjuvant for
enhancing serum and mucosal antibodies to IN administered protein immunogens, and it can promote induction of protein
immunogen-specific CD8 T cells.

2. Methods
2.1. Animals
Twelve female Indian-origin Macaca mulatta, aged 7–15 years,
were cared for in accordance with the Animal Welfare Act and
the NIH ‘‘Guide for the Care and Use of Laboratory Animals”. All
animals were negative for SIV, Simian Retrovirus Type D, and
Simian T-Lymphotropic Virus Type 1. From weeks (wks) 2 to
14, animals were given monthly IM injections of 1.5 mg kg 1
Depo-ProveraTM (Pfizer, New York, NY). All procedures were
approved by Institutional Animal Care and Use Committees at
Tulane and LSUHSC.
2.2. Immunogens
Baculovirus-derived SIVmac251 rgp130 Env protein was from
ImmunoDiagnostics (Woburn, MA). The pVacc4 plasmid
(SHIV89.6P DNA) in saline was produced by Aldevron (Fargo,
ND), and is a derivative of pVacc1 [42] that contains the HIV env
gene of SHIVKB9, a molecular clone of SHIV89.6P, and mutated
SIVmac239 gag and pol genes [43] which result in secretion of noninfectious viral particles. Shigella Invaplex 50 was purified from S.
flexneri 2a cultures as described [44]. Purified replicationincompetent human Ad type 5 vectors encoding SIVmac239 Env
or SIVmac239 Gag-Pol fusion protein [45] were a generous gift
from Dr. Gary Nabel and the NIH Vaccine Research Center,
Bethesda, MD.
2.3. Immunizations
Three groups of macaques (each n = 4) were IN immunized with
1.5 mg naked SHIV DNA plus 0.5 mg SIV gp130 Env protein with or
without InvaplexNAT in a total volume of 250 ml on wks 0, 4, and 8.
Group (Gp) 2 and Gp 3 animals received DNA + protein with 0.25
and 0.5 mg InvaplexNAT, respectively. The individual vaccine
components were mixed 1 h before immunization. On wk 28, all
animals were IN boosted with 1010 particle units (PU) Ad-SIVenv
plus 1010 PU Ad-SIVgag-pol in 200 ml. Immunizations were
performed by pipetting half of each solution into each nostril. After
application, each nostril was immediately pressed shut and
released to ensure coating of internal surfaces.
2.4. Specimen collection and processing
Standard venipuncture was used to collect whole blood for
serum or heparinized blood for peripheral blood mononuclear cells
(PBMC). The PBMC were isolated by density gradient centrifugation on Lymphocyte Separation Medium (VWR, Radnor, PA) and
cryopreserved. Starting on wk 0, cervicovaginal secretions (CVS)
and rectal secretions (RS) were sampled at biweekly or monthly
intervals by consecutive application of 2 premoistened Weck-Cel
sponges (Beaver Visitec, Waltham, MA) in the vagina or rectum
as described [46]. Nasal secretions (NS) were collected at biweekly
intervals starting on wk-2, except on days when IN immunization
was performed. To collect NS, 100 ml DPBS was pipetted into a nostril. The nostril was immediately pressed shut, massaged gently to
hydrate surfaces, then released. A sponge premoistened with 50 ml
PBS was quickly inserted and allowed to absorb fluid for 5 min.
After removal, the procedure was repeated for the other nostril
using a second sponge. Tubes containing sponges were maintained
on wet ice until storage at 80C. To extract secretions, one sponge
was placed in the upper chamber of a Corning SpinX filter (VWR)
that had holes poked in the filter (to prevent clogging by mucus).
The sponge was treated with 100 ml ice-cold PBS containing 0.5%
2
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These assays were performed as described [46] using microtiter
plates coated with goat anti-monkey IgA (Alphadiagnostics, San
Antonio, TX) or goat F(ab’)2 to monkey IgG (MP Biomedicals, Solon,
OH). The standard was a normal rhesus macaque serum containing
known amounts of Ig (kindly provided by Dr. M.W. Russell, University at Buffalo, NY). The secondary antibodies were biotinylated
goat anti-monkey IgA (Alphadiagnostics) or -human IgG (SouthernBiotech Associates: SBA, Birmingham, AL). Absorbance was
recorded at 414 nm after development with streptavidinperoxidase and azino-bis(3-ethylbenzothiazoline-6-sulfonic acid)
(both Sigma). Concentrations were interpolated from 4parameter standard curves constructed with SoftMaxPro software
(Molecular Devices, Sunnyvale, CA).

reaction was stopped by adding 10 ml goat serum. The cells
were then washed and stained for 30 min with anti-CD3
(SP34-2)-Pacific Blue, anti-CD4 (L200)-PerCP-Cy5.5 and anti-CD8
(RPA-T8)-APC-Alex750 (eBioscience, San Diego, CA). Cells were
washed and resuspended in 200 ml Cytofix/Cytoperm. After
20 min, cells were washed with PermWash buffer and stained for
30 min with anti-IFN-c (B27)-FITC, anti-IL-2 (MQ1-17H12)-PE
and anti-TNF-a (MAb11)-PE-Cy7 (eBioscience). Cells were washed,
fixed with 1% paraformaldehyde, then analyzed in an LSRII flow
cytometer. Maximal events were acquired. Compensation Beads
expressing anti-mouse or anti-rat kappa chain antibody were
processed in parallel for each fluorophore-conjugated antibody.
For Live/Dead cell stain and anti-CD3 antibody, compensation
was done using amine-reactive silica beads (Bang’s Laboratories,
Fishers, IN) incubated with these reagents. The FlowJo computer
program (Tree Star, Ashland, OR) was used for data analysis and
Boolean gating. Percentages of cytokine-positive cells in unstimulated cultures (typically 0–0.03%) were subtracted from those in
stimulated cultures. The latter were considered significant if
adjusted percentages were > 0.05% and twice the background.

2.6. ELISA for InvaplexNAT or SIV antibodies

2.8. Statistics

Igepal detergent (Sigma, St. Louis, MO) and protease inhibitors
[46], then ultracentrifuged at 20,000g and 4C. After 45 min, the
upper chamber was replaced with a new upper chamber containing the 2nd sponge, and the procedure was repeated.
2.5. ELISA for total IgA or IgG

Assays for InvaplexNAT antibodies were performed as described
[36] using Immulon I plates (Dynatech, Chantilly, VA) coated overnight with 50 ng per well InvaplexNAT in pH 9 carbonate buffer.
Assays for SIV antibodies were done as described [22] using Fisherbrand high protein-binding plates coated with 100 ng SIV gp130
(ImmunoDiagnostics) or 250 ng SIVmac251 lysate (Advanced
Biotechnologies Inc., Columbia, MD) in PBS per well. Anti-lysate
antibodies are referred to as being ‘‘Gag,Pol”-specific because no
Env protein could be detected in the coated lysate using an antigp130 antibody (ImmunoDiagnostics). Pooled serum from
InvaplexNAT-immunized and SIV-infected macaques were used as
standards. The concentration of antibody in each standard was
calibrated relative to the total IgA or IgG in the normal monkey
serum by coating different portions of a plate with antigen or Ig
capture antibody. Plates were developed as above, except that
the substrate was tetramethylbenzidine (SBA), 1 N H2SO4 stop
solution was added, and absorbance was read at 450 nm. The
specific activity (sp act) in secretions was calculated by dividing
the concentration of Invaplex-, SIV Env- or SIV Gag,Pol-specific
IgA or IgG by the respective concentration of total IgA or IgG.
Secretions were considered antibody-positive if they contained
sp act that was both  mean sp act + 3SD for naïve macaque
secretions and 3.4-fold above the animal’s preimmune sp act. If a
secretion had undetectable antibody, it was assigned the mean
sp act of naïve specimens.

The GraphPad Prism v9 computer program was used for graphing and statistics. Non-parametric statistics were used because of
the small number of animals in each group. Differences between
groups were initially sought using the Kruskal Wallis test. If a significant p value was obtained, Group 2 or Group 3 was subsequently compared to Group 1 using the two-tailed MannWhitney rank sum test to determine if a significant difference
existed. Correlations were done using the two-tailed Spearman
rank correlation test. Only p values  0.05 were considered
significant.
3. Results
3.1. Systemic IgG responses to Env protein immunogen and DNA
encoded antigens
Two doses (0.25 and 0.5 mg) of InvaplexNAT were selected for
testing based on the finding that they induced anti-Invaplex antibodies in IN-immunized humans [38]. In Phase 1 of the study, 3
groups of female macaques (each n = 4) were given 3 monthly IN
immunizations with SHIV89.6 DNA + SIVmac251 Env protein formulated with either PBS, 0.25 mg or 0.5 mg InvaplexNAT. In Group
(Gp) 1 nonadjuvanted control animals, no IgG antibodies to the SIV
Env protein or DNA encoded SIV Gag,Pol antigens were detected by
ELISA in serum collected up to 20 wks after the 3rd immunization
(Fig. 1). In Gp 2 animals that received 0.25 mg InvaplexNAT, the systemic antibody responses were not significantly improved because
only 50% of the animals developed SIV-specific IgG antibodies in
serum. However, co-administration of vaccine antigens with
0.5 mg InvaplexNAT significantly increased SIV Env-specific IgG in
serum of all Gp 3 animals (Fig. 1). Gp 3 animals also had increased
Gag,Pol-specific serum IgG, albeit to a lesser extent (Fig. 1). At their
Phase 1 peak on wk 10, the geometric mean concentrations of SIV
Env- and Gag,Pol-specific IgG in Gp 3 sera were 23– and 9-fold
above preimmune levels, respectively.
To confirm that immunizations with Invaplex generated B cell
memory, all animals were IN boosted during Phase 2 of the study
on wk 28 with Ad-SIVgag-pol plus Ad-SIVenv (Ad-SIV). Anamnestic
responses in Gp 2 and Gp 3 were clearly evident. In Gp 3, the boost
increased Env- and Gag,Pol-specific IgG to levels that were 185- to
62-fold above those measured on wk28, respectively (Fig. 1). In
contrast, Gp 1 controls demonstrated only 7- and 3-fold mean

2.7. Intracellular cytokine staining
Reagents were from BD Biosciences (San Diego, CA) unless
otherwise noted. Cryopreserved PBMC were washed and used for
all T cell assays. One million PBMC were suspended in RPMI1640
medium containing 5% FBS, penicillin, streptomycin, L-glutamine
and 1 mg ml 1 anti-CD28 (clone 28.2) and anti-CD49d (9F10). The
medium was additionally supplemented with DMSO (final 0.2%)
or 2 mg ml 1 pooled peptides encompassing the SIVmac239 Env
or SIVmac239 Gag protein (NIH AIDS Research and Reference
Reagent Program). Positive controls were stimulated with
10 ng ml 1 phorbol myristate acetate (PMA) plus 1 mg ml 1 ionomycin (Sigma). The cultures were incubated at 37C in 5% CO2 for
1 h, spiked with monensin, cultured an additional 5 h, then cooled
to 10C. The following day, PBMC were treated for 5 min with 50 U
ml 1 DNase I (Sigma), washed with PBS, and resuspended in 50 ml
of Aqua Live/Dead cell stain (Invitrogen) in PBS. After 2 min, the
3
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Fig. 1. Systemic IgG responses after nasal DNA/protein vaccination with or without Invaplex. ELISA was used to measure concentrations of serum IgG antibodies to SIV
Env protein immunogen (left panel) and SIV Gag,Pol antigens (right panel) encoded by the DNA vaccine. Shown are geometric means with SEM. Black arrows indicate when
immunizations with DNA/protein ± InvaplexNAT were performed. The red arrow indicates when Ad-SIV boosting was done. Asterisks indicate time points when Gp 3 had
significantly greater antibody concentrations than Gp 1 (p  0.05 by Mann-Whitney). Gp 2 antibody levels did not differ significantly from Gp 1 at any time. (For
interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

antibodies. However, all Gp 3 animals did have Env IgA in CVS or RS
after the 2nd or 3rd immunization, and the magnitude and longevity of these genital tract and intestinal IgA responses was modestly
increased by the Ad-SIV boost (Fig. 2).
NS from Gp 3 animals also contained greater Env IgA sp act than
control animals (Fig. 2). For Gp 3, peak increases in Env IgA antibodies during Phase 1 were 30-fold and these were dramatically
increased by the Ad-SIV boost to levels 670-fold above preimmune.
The nasal IgA response to Env was also surprisingly long-lived.
Eight months after the Ad-SIV boost, Env IgA in Gp 3 NS was still
elevated by 53-fold (Fig. 2). Interestingly, when compared to CVS,
the peak nasal antibody response was delayed by 2–4 weeks, a
finding similarly observed in humans [47]. The magnitude of the
nasal Env IgA response was also greater than the distal IgA
responses (Fig. 2), consistent with reports that greatest mucosal

increases in these antibodies (Fig. 1). Thus, a 0.5 mg dose of Invaplex was able to enhance systemic IgG responses and to generate
antigen-specific memory B cells against both the Env protein
immunogen and DNA encoded Gag and Pol proteins.
3.2. Local and distal mucosal IgA responses to Env protein immunogen
The magnitude of the anti-SIV Env mucosal IgA responses generated in mucosal compartments of immunized animals was compared after calculating the Env IgA sp act (ng anti-Env IgA per mg
total IgA) in secretions. As shown in Fig. 2, Gp 1 nonadjuvanted
control animals completely failed to develop anti-Env IgA antibodies in distal CVS or RS during both phases of the study. Overall, the
Gp 2 animals did not respond better than controls because the
same 2/4 serum IgG non-responders also failed to develop mucosal

Fig. 2. IgA responses to Env protein immunogen. The Env IgA sp act (ng anti-Env IgA antibody per mg total IgA) was calculated after measuring concentrations of Envspecific and total IgA by ELISA. The geometric mean sp act / SEM is shown for nasal secretions (NS), cervicovaginal secretions (CVS), rectal secretions (RS), and sera. Note
that NS were not collected for antibody analysis on days when IN immunization was performed with DNA/protein ± InvaplexNAT (black arrows) or Ad-SIV (red arrow).
Asterisks denote the wks when Gp 3 had significantly greater sp act than Gp 1. Crosses indicate when Gp 2 had significantly greater sp act than Gp 1 (all p  0.05 by MannWhitney). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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antibody responses are generated at sites of antigen administration
in humans [16,48].
Currently, there are no sufficiently specific and sensitive antimacaque secretory component antibodies available to confirm that
secretions of these animals contained secretory antibodies (polymeric IgA or IgM that has undergone pIgR-mediated basolateralto-apical transport across epithelial cells). However, no Env IgA
was found in serum of any of the Gps during Phase 1 (Fig. 2). Therefore, the Env IgA in secretions of Gp 3 animals during Phase 1 must
have come from the mucosae, rather than serum. During Phase 2, a
mucosal origin for the Env IgA in RS and CVS could not be confirmed because the Ad-SIV boost generated Env-specific IgA in
serum which was similar in levels and correlated with Envspecific IgA in RS or CVS on wks 30–40 (all p  0.0006). However,
a mucosal anti-Env IgA response was elicited in the nasal cavity of
Gp 3 animals on wks 32–40 because the Env IgA sp act in NS was
significantly greater (p < 0.05 at every time point) and not correlated with the Env IgA sp act in serum (p = 0.1626).
During Phase 1, SIV Env-specific IgG was also measured in Gp 1
and 3 NS (Supplemental Fig. 1). Starting on wk10, Env IgG was
detected in NS of both Gps 1 and 3 and peaked on wk12 at levels
that were 4.1- and 8.5-fold above preimmune, respectively. These
presumably represent local IgG responses because Gp 1 controls
did not have significant Env-specific IgG in serum at this time,
and the Env IgG in serum versus NS of Gp 3 animals were not correlated (p = 0.1647). Thus, nasal vaccination in the absence of Invaplex induced a weak nasal anti-Env IgG but not IgA response,
whereas vaccinations with Invaplex induced a strong nasal IgA
response. Invaplex also clearly functioned as an adjuvant for
increasing distal mucosal IgA responses to the Env protein.

serum. Group 1 nonadjuvanted animals did not develop Gag,Pol
IgA in distal CVS and RS, though slight elevations were found in
NS of these controls after the Ad-SIV boost (Fig. 3). The CVS and
NS of Gp 3 animals contained the greatest Gag,Pol IgA sp act, which
again could be attributed to mucosal synthesis during Phase 1 due
to the absence of Gag,Pol-specific IgA in serum (Fig. 3).
In Gp 3, the Ad-SIV IN immunization dramatically boosted the
Gag,Pol IgA sp act in NS, with the peak 19-fold Phase 1 increase
climbing to 200-fold on wk 34 (Fig. 3). The increases of Gag,Pol
IgA sp act in NS of Gp 3 animals were both significantly greater
(p < 0.05) and not correlated with those in serum on wks 34–40
(p = 0.5450). The Gag,Pol IgA in Gp 3 NS was still elevated over
pre-immune values by 9-fold at 8 months following the Ad-SIV
boost (Fig. 3). In contrast to Env IgA results, Gp 3 animals did not
develop Gag,Pol IgA in RS (Fig. 3), presumably due to introduction
of lower antigen dosages by the DNA vaccine.
For IgG, no Gag,Pol-specific IgG was found in NS of Gp 1 control
animals (Supplemental Fig. 1). The NS from Gp 3 animals did have
low levels of Gag,Pol IgG on wks 6–16, which peaked at 6-fold on
wk 10, but these were likely transudated from serum because
the Gag,Pol IgG sp act in NS was both lower and correlated with
that in serum (p = 0.0200).
These results indicate that Invaplex can function as an adjuvant
to enhance nasal and genital tract IgA antibodies to proteins
encoded by a nasal DNA vaccine. Induction of rectal antibodies
may require larger vaccine doses or more optimal delivery methods such as a spray device to deposit vaccine and adjuvant more
thoroughly on the nasal mucosae.

3.3. Local and distal mucosal IgA responses to DNA vaccine antigens

Antibodies generated against Invaplex were also measured in
sera and NS collected from wk 2 to wk 30. None of the groups
had significant (>3.4-fold) increases of anti-Invaplex IgG or IgA in
sera (not shown). NS were also negative for Invaplex-specific IgG
(not shown). However, starting on wk 6, Invaplex-specific IgA

3.4. Induction of Invaplex-specific nasal IgA antibodies

Systemic and mucosal IgA responses to Gag,Pol antigens in the
DNA encoded SHIV particles (Fig. 3) developed in parallel with Env
IgA responses but were of lower magnitude, as found for IgG in

Fig. 3. IgA responses to DNA encoded Gag,Pol antigens. The Gag,Pol IgA sp act (ng anti-Gag,Pol IgA antibody per mg total IgA) was calculated after measuring Gag,Polspecific and total IgA by ELISA. The geometric mean sp act / SEM is shown for NS, CVS, RS, and sera. Asterisks denote the wks when Gp 3 had significantly greater sp act
than Gp 1 (p  0.05 by Mann-Whitney). Gp 2 did not have significantly greater sp act than Gp 1 at any time.
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p = 0.0286; Fig. 6). One month after the Ad-SIV boost (wk 32),
IFNc-secreting Env-specific T cells appeared again, with IL-2- and
TNFa-producing Env-specific T cells becoming evident at this time
(Fig. 6B and D). On wk 32, Gp 3 had significantly greater frequencies of Env-specific CD4 + and CD8 + T cells secreting either IFN-c
or TNF-a when compared to Gp 1 (all p < 0.05; Fig. 6B and D). Analysis of the wk32 Env-specific T cells by Boolean gating indicated
that the majority of the CD4 (not shown) and CD8 T cells
(Fig. 6E) were monofunctional, followed by dual producers of IFNc
and TNFa. The frequencies of monofunctional and polyfunctional T
cells did not differ significantly between the groups.
During Phase 1, frequencies of SIV Gag-specific T cells exceeding
0.05% were not detected by ICS. After Ad-SIV boosting, IFNcproducing Gag-specific CD4 (not shown) and CD8 T cells (Fig. 6F)
were observed in low frequencies, which did not differ significantly
between the groups. These results suggest that Invaplex may not
adjuvant T cell responses to naked DNA vaccine co-administered
in the nasal cavity, but it can enhance cellular responses, including
CD8 T cell responses, to protein immunogens.

Fig. 4. Nasal IgA responses to InvaplexNAT. The Invaplex IgA sp act (units antiInvaplex IgA per mg total IgA) in NS was determined after measuring anti-Invaplex
IgA and total IgA by ELISA. The fold increase was then calculated by dividing the
postimmunization sp act by the preimmunization sp act. Geometric mean and SEM
are presented. Arrows indicate when immunizations with DNA/protein ± InvaplexNAT
were performed. Postimmunization fold increases had to be 3.4-fold to be
considered significant.

4. Discussion

was detected in NS of Gp 2 and 3 animals (Fig. 4). On wk 12, the
Invaplex IgA sp act in Gp 2 and 3 peaked at levels 56- and 94fold above preimmune, respectively. On wk 30, they were still elevated by 28-fold in Gp 3 NS (Fig. 4). Pre-existing IgA to Invaplex has
not prevented Invaplex from acting as an IN adjuvant in mice [39].
Nevertheless, future studies will be required to determine whether
the induction of these adjuvant-specific nasal IgA antibodies in
humans may preclude use of InvaplexNAT in IN booster
vaccinations.

In this study, we show that IN co-delivery of Shigella
InvaplexNAT with a SHIV DNA/SIV Env protein formulation in NHP
was able to adjuvant mucosal IgA and systemic IgG responses to
both the protein immunogen and antigens encoded by the DNA.
The IN DNA/protein vaccinations with 0.5 mg InvaplexNAT followed
by IN boosting with Ad-SIV induced extremely high levels of SIV
Env-specific IgA in NS, which were still elevated over preimmune
levels by 56-fold after 8 months. It is well-established that greatest
IgA responses are generated in the mucosa at sites of antigen exposure [16,20,48], but these nasal IgA responses are notable because
HIV- or SIV-specific IgA responses of this magnitude and longevity
have not previously been reported in macaques. In fact, generating
strong mucosal IgA responses has been somewhat problematic in
this species and appears to require larger vaccine dosages when
compared to humans [49]. It is for this reason that we used such
a high dose of Env immunogen.
It is possible that the induction of HIV- or SIV-specific IgA antibodies in macaques has been difficult because generating IgA
responses in this species is dependent on the production of a specific soluble factor that has not been adequately elicited by most vaccines. For example, class-switching to IgA2 in human B cells

3.5. T Cell responses to protein immunogen
A goal of HIV vaccines is to induce Th1-type antiviral cellular
responses. Therefore, we used intracellular cytokine staining
(ICS) and flow cytometry to evaluate SIV-specific IFNc, TNFa and
IL-2 producing T cells induced in blood of animals at 2 wk intervals
after immunization. The gating strategy and representative results
are illustrated in Fig. 5. During Phase 1 of the study, IFNcproducing Env-specific CD4 and CD8 T cells were observed on wk
12 (Fig. 6A and C), when they peaked, as observed for nasal antibodies. Both Gp 2 and Gp 3 animals had significantly greater frequencies of these cells than Gp 1 controls (all comparisons
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IFN gamma (FITC)
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PMA/ionomycin
IFN gamma (FITC)
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SSC
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lymphocytes
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Fig. 5. Flow cytometric gating strategy. For ICS with PBMC, doublets were first excluded. Gating was then done on lymphocytes, CD3 T cells negative for Live/Dead viability
dye, and CD8 or CD4 T cells. Each T cell subset was then evaluated for cytokine. Shown are representative results for IFNc-producing CD8 T cells in wk12 PBMC cultures
treated with medium alone (unstimulated), SIV Env peptide (stimulated) or PMA/ionomycin as a positive control.
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Fig. 6. T cell responses after DNA/protein immunization and Ad-SIV boosting. The frequency of SIV Env-specific CD4 (A, B) or CD8 (C, D) T cells producing IFNc, TNFa, or
IL-2 was measured by ICS after peptide stimulation of PBMC. Results are depicted as minimum-to-maximum whisker box plots for wk12 (4 wks after the 3rd DNA/protein
immunization with or without Invaplex) and wk32 (4 wks after the Ad-SIV boost). (E) Boolean gating was used to determine the frequencies of monofunctional and
polyfunctional Env-specific CD8 T cells on wk32. There were no differences between the groups. (F) Gag-specific IFNc-secreting CD8 T cells detected on wk32 by ICS. *p  0.05
by Mann-Whitney when compared to the control group.

protein, in the absence of adjuvant, could induce specific IgA in
secretions of both the distal female genital tract and rectum [16].
Importantly, a 10-fold lower nasal dose of protein was able to generate genital tract IgA responses comparable to those observed in
vaginally-immunized women [16]. However, the magnitude of
the IgA response in the rectum of IN-immunized women was quite
modest. We hypothesized that IN co-delivery of immunogen with a
strong adjuvant would improve distal IgA responses by increasing
the frequency of activated B cells with homing receptors for distal
tissues. Indeed, IN DNA/protein immunizations with InvaplexNAT
did generate genital tract IgA responses to both the protein
immunogen and DNA encoded Gag,Pol antigens that were comparable to those observed in the nasal cavity. Immunizations with
Invaplex also enhanced the distal rectal IgA response to Env protein. However, the magnitude of the rectal IgA response to Env
was low, and no Gag,Pol-specific rectal IgA was detected. Therefore, IN administration of vaccines may not induce rectal IgA
responses of sufficient magnitude to prevent rectal HIV transmis-

requires A Proliferating Ligand (APRIL), which is produced by
mucosal epithelial cells and myeloid dendritic cells [50]. Interestingly, the synthesis of APRIL by human intestinal epithelial cells
can be triggered by Salmonella LPS, a Toll-like receptor 4 (TLR4)
ligand [50]. In mice, TLR-4 signaling in intestinal epithelial cells
recruits B cells to the intestinal lamina propria [51]. Since Shigella
LPS is a major component of Invaplex, an interaction with TLR-4 on
nasal epithelium or local dendritic cells may have stimulated
secretion of APRIL or another IgA inducing protein [52] that
promoted B cell recruitment to nasal tissues and their subsequent
differentiation into IgA antibody-secreting cells. An InvaplexNATstimulated production of an IgA-inducing factor by epithelial cells
in the nasal cavity would explain why the magnitude of nasal IgA
responses to SIV Env, SIV Gag,Pol and Invaplex were much greater
than the nasal IgG responses to these antigens.
We had hoped that IN immunization with InvaplexNAT would
elicit greater IgA responses in the rectum. In a previous study with
women, we found that IN vaccination with a highly immunogenic
7
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compared to blood [19,22,23,45], and although monofunctional T
cells typically dominated in blood, more heterogeneous profiles
of IFNc, TNFa and IL-2 secreting T cells were observed in rectal
or vaginal tissues [19].
A caveat of our study is that the animals were given DepoProvera (medroxyprogesterone) during the adjuvant phase. This
was done to prevent ovulation and menses [60] because, at ovulation, total IgG and IgA in CVS of NHP [61], like humans [62], declines dramatically, making antibody detection difficult, and, during
menses, the blood in CVS prevents accurate assessment of genital
tract antibody responses. CVS collection cannot be scheduled
around these menstrual cycle phases at most Primate Centers
because exam rooms need to be reserved well in advance. Since
we could not afford to exclude CVS with insufficient IgA or blood
due to the small numbers of macaques in our study, we opted to
administer Depo-Provera (DP). This contraceptive has immune
suppressive properties [63,64], but they appear to be largely confined to the cervicovaginal mucosa in humans and NHP [65–67].
DP has not altered systemic antibody responses induced by rubella
vaccination of women [68] or by intravenous (IV) immunization of
macaques with nonpathogenic SHIV89.6 [66]. DP-treated female
macaques IV-immunized with SHIV89.6 were also reported to
develop strong gag-specific T cell responses with greater polyfunctionality in blood, and, following IV infection with SIV, they better
controlled viremia when compared to untreated macaques [67]. In
contrast, DP-treated macaques infected with SIV or pathogenic
SHIV by the vaginal route have demonstrated less TNFa, more T
regulatory cells and delayed appearance of IFNc-producing gagspecific T cells in the periphery [67,69], suggesting that DP may
dampen immune induction specifically in the female genital tract.
On the other hand, administration of DP to mice IN-immunized
with a CpG-adjuvanted herpes protein was reported to reduce
titers of specific IgA in vaginal secretions [70]. To determine if this
might also occur in NHP given DP, we performed a preliminary
study in which 12 female rhesus macaques were IN-immunized
with the whole-inactivated Dukoral ‘‘oral” cholera vaccine (containing 100 mg CTB) [16] at monthly intervals a total of 3 times.
Starting 2 weeks before the first immunization, six of these animals
were given monthly injections of 1.5 mg kg 1 DP. No significant
differences in the kinetics or magnitude of the CTB-specific serum
IgG, rectal IgA and vaginal IgA response were observed between
the untreated and DP-treated animals when measured by ELISA
[16] at biweekly intervals up to week 16, the last time point in
the study (Kozlowski, unpublished observations). However, T cell
responses were not measured. Therefore, we still cannot exclude
the possibility that DP may hinder development of polyfunctional
T cells in IN-immunized NHP. Thus, until the current study is
repeated in cycling macaques, the immune responses observed
here should be considered to best reflect those that would be generated in pre-menopausal women using DP.
In conclusion, InvaplexNAT has good adjuvant activity for augmenting both humoral and cellular immune responses to protein
immunogens given in the nasal cavity of NHP. This strongly suggests it would similarly augment mucosal and systemic antibody
responses to IN subunit vaccines in humans. InvaplexNAT could also
adjuvant mucosal and systemic antibody responses to IN DNA
vaccines that encode secreted proteins. In addition to potentially
promoting vaccine-mediated protective immunity to sexuallytransmitted pathogens, the inclusion of Invaplex in IN vaccines
for influenza, SARS CoV-2 or other air-borne pathogens, for which
S-IgA antibodies have clearly been associated with protection [71],
could be highly beneficial for preventing respiratory tract infections in humans.
Disclaimer
Some authors (RW Kaminski and EV Oaks) are employees of the
U.S. Government. Material has been reviewed by the Walter Reed

sion. Local delivery of vaccine would likely produce superior rectal
IgA responses [16,48,53]. A potential problem is that rectal immunization with a variety of immunogens [16,48,53,54], including a
live attenuated vaccine [55], has proved poorly effective for induction of IgA antibodies in the female genital tract of NHP and
women. Vaginal immunization can similarly produce highly
restricted local antibody responses [16,48,53]. Since IN immunization is more effective for generating antibodies in CVS than in RS, a
regimen consisting of IN priming followed by rectal boosting might
be most effective for induction of antibodies in both rectal and
female genital tract secretions.
In macaques immunized with Invaplex, antibody responses to
the Gag,Pol antigens encoded by the DNA vaccine component were
of lower magnitude than those to the SIV Env protein immunogen.
This was anticipated because doses of SHIV particles budding from
pVacc4-transfected cells in the nasal mucosa were probably much
lower than the amount of Env protein that was internalized. In
addition, nasal immunization of macaques with pVacc4 or similar
plasmids has not induced much antibody in sera or secretions,
even after nasal boosting with MVA-SHIV [22,43] and VLP [19].
Thus, we were surprised to find Gag,Pol-specific IgG in serum
and IgA in CVS prior to the Ad-SIV boost. Co-delivery of InvaplexNAT
with DNA may have stimulated the production of chemokines that
recruited or activated immature DC at a time that was optimal for
capture of SHIV particles in nasal tissue or draining lymph nodes.
We have found that treatment of polarized colonic epithelial cells
with InvaplexNAT induces production of GM-CSF, IL-1 and IL-4,
which could facilitate maturation of DC (Kaminski and Oaks,
unpublished observations).
Although the DNA/protein immunizations with InvaplexNAT did
not have apparent effects on development of T cell responses to the
DNA encoded Gag protein, InvaplexNAT did enhance CD4 and CD8
Th1-type responses to the Env protein immunogen. We believe
InvaplexNAT adjuvanted Env specific-CD8 T cell responses by promoting cellular internalization of the protein by DC and other
antigen-presenting cells. The Shigella Ipa proteins are normally utilized by shigellae to invade epithelial cells by inducing actin polymerization and phagocytosis [56]. In previous studies, we have
found that the IpaB and IpaC proteins mediate cellular uptake of
Invaplex and co-administered proteins or DNA, suggesting that
the biological activities of these invasin proteins are retained in
InvaplexNAT [40]. The inherent ability of the complex to induce
uptake, combined with the TLR-4 ligand activity of the LPS, are
likely responsible for the adjuvant activity of Invaplex. More
recently, a second generation Invaplex product has been developed
[57] which is assembled into a large complex using purified
Shigella LPS, IpaB and IpaC. Artificial Invaplex, or InvaplexAR, is more
compatible with large scale manufacture, is customizable and welldefined, facilitating regulatory compliance. InvaplexAR also retains
the adjuvant properties attributed to InvaplexNAT described here.
Phase 1 studies evaluating InvaplexAR delivered IN demonstrated
the product was safe, well-tolerated and induced robust systemic
and mucosal immune responses directed to the three major product
components (Kaminski, manuscript in preparation).
The immunological processes that govern the development of
polyfunctional T cells are not understood. However, antigen dose
may be a factor. Lower doses of vaccine have been reported to promote polyfunctionality [45,58,59]. Larger doses have been found to
bias cellular immunity toward monofunctional IFNc responses
[45]. Since we administered a high dose of Env protein immunogen, this may explain why only IFNc-producing Env-specific T cells
were observed during the adjuvant phase of our study. It is possible, though, that polyfunctional T cells were generated in mucosal
tissues of our animals. In macaques immunized in the respiratory
tract with DNA/MVA- or Ad5-based SIV vaccines, greater frequencies of virus-specific T cells have been detected in mucosal tissues
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